Immunoglobulin E specific for Bouteloua gracilis pollen allergens (sIgE (Bouteloua gracilis))

Immunoglobulin E (IgE) antibodies specific for Bouteloua gracilis (Blue Grama grass) pollen allergens are the primary mediators of Type I hypersensitivity reactions in individuals sensitized to this grass species (Galli & Tsai, Nature, 2012). These antibodies are produced by B cells and plasma cells following initial exposure to the pollen and subsequently bind to high-affinity FcεRI receptors on the surface of mast cells and basophils. Upon re-exposure, the Bouteloua gracilis allergens cross-link the receptor-bound IgE, triggering the immediate release of inflammatory mediators such as histamine, proteases, and cytokines (AAAAI, 2024). This cascade results in the clinical manifestations of allergic rhinitis, conjunctivitis, and allergic asthma. Therapeutic interventions targeting these specific IgE antibodies include the use of anti-IgE monoclonal antibodies like Omalizumab, which sequester free IgE, and allergen-specific immunotherapy (AIT), which aims to modify the underlying immune response toward tolerance (NCBI, 2023).

Other names

Blue grama grass-specific IgEAnti-Bouteloua gracilis IgESpecific IgE to Blue grama grass pollenIgE anti-g17

Omalizumab binds to the Cε3 domain of the IgE molecule, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils (NCBI, 2023). Allergen-specific immunotherapy (AIT) involves the administration of increasing doses of Bouteloua gracilis pollen extract to induce peripheral T-cell tolerance and promote the production of 'blocking' IgG4 antibodies, which compete with IgE for allergen binding (StatPearls, 2023).